FDA approves elranatamab (ELREXFIO™) for relapsed or refractory myelomaAccess, MyelomaAugust 21, 2023
European Commission approves talquetamab for the treatment of relapsed and refractory myelomaAccess, MyelomaAugust 22, 2023
EMA recommends expansion of melphalan flufenamide (Pepaxti®) marketing authorisationAccess, MyelomaSeptember 18, 2023
EMA CHMP recommends non-renewal of marketing authorisation for Blenrep®Access, MyelomaSeptember 22, 2023
EMA CHMP gives positive recommendation to elranatamab for the treatment of relapsed or refractory myelomaAccess, MPE, MyelomaOctober 13, 2023
EMA CHMP gives positive opinion on CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaJanuary 30, 2024
MPE gives feedback on the proposed implementing act supporting the EU Health Technology Assessment regulationAccess, MPEApril 8, 2024
AMEN provides medical information for Arabic speakers in Israel and beyondAccess, MPEFebruary 13, 2024
EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaFebruary 23, 2024
